At the Pharma CI Conference (Sept 25–26, 2024), leaders discussed how shifts like the IRA’s impact on drug pricing, AI in R&D, and shifting regulatory regimes are reshaping life sciences CI. Read this summary to grasp the conference’s breakout trends and strategic implications.
Pharmaceutical companies need more than public data to stay ahead. Learn how integrating pharmaceutical primary intelligence fills critical gaps and uncovers real-time competitive insights.
Competitive insight isn’t one-size-fits-all. We delve into multi‑pronged data collection, covering pricing, packaging, discounts, and bundling, to identify optimal tactics across segments and contexts. This post breaks down how to benchmark pricing strategies and create differentiated value propositions.
Through analysis of IO clinical trials (2018–2022), we reveal how top‑20 pharma concentrate on mAb trials globally, while smaller firms explore innovative modalities like BsAb and CAR‑T, and how China is emerging as an IO hub. These patterns offer strategic cues for reshaping your trial portfolio and R&D focus.
This first article, part of a three-post series, focusses on need for such a meeting and underlines the impact of accelerated approvals in the field of Oncology.
Increasingly, employees at all levels of the organization are being called upon to support the competitive intelligence function. Will you be ready? Will you know what to say? What to ask? Read more to learn how to increase effectiveness by simply asking the right questions.
The COVID-19 pandemic has had a very strong impact on all global economies across multiple sectors. Its impact on the US Pharma industry was significant in the first quarter, causing most companies to adjust and realign their businesses in response to the outbreak. The pandemic not only had a direct impact on Q1 revenues, but also affected overall drug development …
Before COVID-19 transpired executives were concerned with their strategic assumptions and the results of getting them wrong. A February 2020 Gartner study cited lack of confidence in strategic assumptions as the leading corporate risk among senior executives across a diverse set of industries and global geographies in Q4 2019. A strategic assumption can be defined as the unstated belief that something is likely to occur to enable an achievable strategic goal. Depending on the …
The COVID-19 outbreak generated widespread concern over how pharmaceutical, biotechnology, and medtech companies would cope with stringent national and regional lockdowns. Financial results from Q1 provide the first indicator of how this public health crisis will impact this industry and what the future may hold. By early May, earnings for most of the significant players in the pharma industry had been announced, …
While times are tough and it seems as if the economy is in freefall, the fact remains – customers are still making financial choices on what, where, and how much to spend. The mental calculus is changing, however, there is no need to panic, we have seen this before. A little over ten years ago, before joining the Sedulo team, …
